Teva-Barr deal complete
This article was originally published in The Tan Sheet
Executive Summary
Teva Pharmaceutical Industries' $7.5 billion acquisition of Barr Laboratories is complete, the Jerusalem-based generics firm says Dec. 23. Teva will pay an additional $1.5 in debt settlement, and receive the rights to Barr's OTC emergency contraceptive Plan B and its women's health portfolio (1"The Tan Sheet" July 21, 2008, In Brief). Under an antitrust settlement with the Federal Trade Commission announced Dec. 19, the combined entity will divest some generic drugs to Watson Pharmaceuticals and Qualitest Pharmaceuticals to complete the acquisition
You may also be interested in...
Teva buys Barr
Jerusalem-based generic drug manufacturer Teva Pharmaceuticals Industries signs an agreement to purchase Barr Laboratories, manufacturer of OTC emergency contraceptive Plan B, for $7.46 billion plus the assumption of net debt of $1.5 billion, the firms say July 18. The companies expect the deal to close in late 2008. Teva looks to the acquisition to enhance its position in the U.S. and European markets. "The combined company will have an unmatched global platform, operate directly in more than 60 countries and employ approximately 37,000 people worldwide," according to a release. Additionally, the acquisition will boost Teva's specialty pharmaceutical platform with the addition of Barr's women's health portfolio, the firms say...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.